According to our new research study on “Glioma Treatment Market Forecast to 2030 – Geography Analysis by Disease, Treatment Type, Grade, End User, and Geography,” the glioma treatment market size is expected to reach US$ 8,291.3 million by 2030 from US$ 4,139.0 million in 2022; it is estimated to register a CAGR of 9.1% from 2022 to 2030. The report highlights trends prevailing in the market and the factors driving and hindering the glioma treatment market growth. The growth of the market is attributed to the initiatives by regional and state governments to provide patients access to treatment and increase in prevalence of high-grade glioma. However, the high cost of diagnosis hinders the market growth.
Glioma is a condition that covers a broad spectrum of brain and spinal cord tumors that concern the glial cells in the brain function and can be fatal depending on the location and severity of the tumor. Astrocytoma, brainstem gliomas, ependymoma, mixed gliomas, oligodendrogliomas, and optic pathway gliomas are the various types of gliomas. Common glioma symptoms include headache, nausea, vomiting, confusion, and a decline in brain function. Glioma can be treated in a variety of ways which include radiation therapy for glioma, chemotherapy, glioma-targeted therapy, and surgery. Effective treatment of glioma may be available from late clinical pipeline drugs.
Region Analysis – Glioma Treatment Market
Glioma Treatment Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Glioma Treatment Market Analysis Report | Size & Share Overview 2030
Download Free Sample
Based on disease, the glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. In 2022, the astrocytoma segment held the largest share of the market and is estimated to record at a significant CAGR of 9.4% during 2022–2030. Astrocytomas, also called malignant gliomas, are often developed in the brain’s cerebral hemispheres. Anaplastic astrocytoma is a type of rare malignant brain tumor. Astrocytomas tumors develop from astrocytes, star-shaped brain cells. Astrocytes and similar cells are called glial cells, and the tissue they form is called glial tissue, which is developed in the brain or spinal cord. Tumors that arise from glial tissues include astrocytomas are referred to as gliomas. The symptoms of anaplastic astrocytomas vary depending on the tumor site and size. The line of treatment for anaplastic astrocytoma is maximal surgical removal, followed by a radiation therapy. The line of treatment may include a combination of neurosurgery, radiation therapy, or chemotherapy.
Avid Bioservices, Inc.; Merck Sharp & Dohme Corp.; Mylan N.V; Novartis AG; and F. Hoffmann-La Roche Ltd. are among the noteworthy players offering products that are used in glioma treatment. An upsurge in activities to raise public awareness of this condition and its treatment, coupled with the increasing prevalence of this disease, are among the major factors fuelling the glioma treatment market growth. In addition, companies operating in the market for the anaplastic astrocytoma segment may derive growth opportunities from growing R&D efforts and new, untapped market segments.
Geographically, the glioma treatment market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The glioma treatment market in North America is segmented into the US, Canada, and Mexico; the US holds the largest share of the market in this region. The market growth is mainly attributed to the increasing brain tumor cases, rapid technological innovations, and developing healthcare infrastructure. According to a report published by the National Brain Tumor Society in 2023, glioblastoma is one of the deadliest, most complex, and treatment-resistant forms of cancer. Over 14,490 Americans are projected to receive a GBM diagnosis in 2023, accounting for ~50.1% of all primary malignant brain tumors. Prominent players in the North American market are focusing on various growth strategies such as mergers, acquisitions, partnerships, and new product launches to expand their geographic presence and enhance their product offerings. For instance, Elekta, a Sweden-based company, collaborated with GE Healthcare to bring innovations in the field of radiation oncology. Through this collaboration, hospitals would be provided with a wide range of treatments for cancer patients requiring radiation therapy.
The US holds a significant share of the glioma treatment market in North America. The market growth in this country is primarily driven by the increasing prevalence of brain tumor, growing technological advancements in glioma treatment, and the rising number of smokers. According to the American Society of Clinical Oncology (ASCO), in 2022, nearly 24,530 adults (13,840 men and 10,690 women) are estimated to be diagnosed with primary cancerous tumors of the brain and spinal cord in the US. Brain tumors are the primary central nervous system (CNS) malignancies, which account for 85–90% of all primary CNS cases. The demand for faster treatment is growing with the rising number of brain tumor cases. According to the Brain Tumor Registry of Canada, 4 out of 100,000 people in Canada suffer from glioblastoma, and nearly 1,000 Canadians are diagnosed with glioblastoma each year. The glioblastoma treatment market players are adopting various organic and inorganic strategies to succeed in the Canadian market. In February 2021, Medexus Pharmaceuticals Inc. initiated the commercial launch of Gleolan in Canada, which was previously only distributed under the Health Canada special access program. Gleolan is an imaging agent that causes high-grade gliomas (malignant and rapidly progressing brain tumors) to fluoresce under blue light, helping neurosurgeons better visualize these gliomas for complete removal. There are currently no other approved optical imaging agents in Canada for visualizing malignant tissues during glioma surgery. Further, developing healthcare infrastructure, increasing investments in research and development, and improvements in treatment procedures are anticipated to drive the glioma treatment market in Mexico during 2022–2030.
Impact of COVID-19 Pandemic on Glioma Treatment Market
During the pre-COVID scenario, continuous research and development activities were carried out for the effective treatment of glioma including surgical resection followed by radio chemotherapy and chemotherapy for patients’ higher survival rate. Major players in the market with funding from the National Institute of Health were focusing on various growth strategies, for instance, R&D in nanotechnology for the options for glioma treatment. These activities were delayed for certain period, as the focus of treatment changed after the COVID-19 outbreak.
The COVID-19 pandemic disrupted healthcare systems, leading to concerns about its subsequent impact on non-COVID disease conditions. Cancer diagnosis and treatment are time-sensitive and were significantly affected by these conditions. The activities of each cancer discipline have been adversely affected by the COVID-19 pandemic. In addition, childhood malignant brain tumors are characterized by rapid growth and require early diagnosis and appropriate treatment. Therefore, delaying or modifying treatment can compromise its effectiveness and reduce patient survival. Due to the fear and pressure of SARS CoV2 infection, changes in the decision-making process of children with brain tumors may have a negative impact on their final outcome to certain extent.
F. Hoffmann-La Roche Ltd; Arbor Pharmaceuticals, LLC; Merck and Co., Inc.; Sun Pharmaceutical Industries Ltd; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Amneal Pharmaceuticals, LLC; Karyopharm Therapeutics, Inc.; and Biocon Ltd Company are among the leading companies operating in the glioma treatment market. These players focus on expanding and diversifying their market presence by acquiring a novel customer base and tapping prevailing business opportunities in the glioma treatment market.
The report segments the glioma treatment market as follows:
Based on disease, the glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. Based on treatment type, the glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. Based on grade, the glioma treatment market is bifurcated into low grade and high grade. Based on end user, the glioma treatment market is bifurcated into hospital & clinics and ambulatory surgical centers. Geographically, the glioma treatment market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com